Mimedx (MDXG) Long-Term Deferred Tax (2015 - 2026)
Mimedx (MDXG) posted Long-Term Deferred Tax of $27.3 million for Q2 2026, up 13.13% sequentially from $24.1 million in Q1 2026, and little changed YoY from $27.4 million in Q2 2025.
Mimedx (MDXG) Long-Term Deferred Tax (2015 - 2026) Analysis & Trends
Mimedx has reported Long-Term Deferred Tax for 7 years, with the latest figure at $27.3 million in Q2 2026.
- Quarterly Long-Term Deferred Tax changed 0.37% year-over-year to $27.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $27.3 million (changed 0.37% YoY) and the FY2025 annual result came in at $19.6 million, down 30.77% from the prior year.
- Long-Term Deferred Tax rose to $27.3 million in Q2 2026 per MDXG's latest filing, from $24.1 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $40.8 million in Q4 2023 and troughed at $19.6 million in Q4 2025.
- A 4-year average of $29.1 million and a median of $27.7 million in 2025 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2025 and 2026: Long-Term Deferred Tax plunged 30.77% in 2025, then slipped 0.37% in 2026.
- Over 4 years, Long-Term Deferred Tax stood at $40.8 million in 2023, then slumped by 30.58% to $28.3 million in 2024, then slumped by 30.77% to $19.6 million in 2025, then surged by 39.29% to $27.3 million in 2026.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $27.3 million, $24.1 million, and $19.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.30 Mn |
| Mar 31, 2026 | 24.13 Mn |
| Dec 31, 2025 | 19.60 Mn |
| Sep 30, 2025 | 21.65 Mn |
| Jun 30, 2025 | 27.40 Mn |
| Mar 31, 2025 | 27.69 Mn |
| Dec 31, 2024 | 28.31 Mn |
| Sep 30, 2024 | 30.64 Mn |
| Jun 30, 2024 | 33.44 Mn |
| Mar 31, 2024 | 38.75 Mn |
| Dec 31, 2023 | 40.78 Mn |
| Dec 31, 2017 | 25.54 Mn |
| Sep 30, 2017 | 17.67 Mn |
| Jun 30, 2017 | 10.14 Mn |
| Mar 31, 2017 | 9.53 Mn |
| Sep 30, 2016 | 7.02 Mn |
| Jun 30, 2016 | 7.08 Mn |
| Mar 31, 2016 | 4.94 Mn |
| Dec 31, 2015 | 14.84 Mn |